Analysts Set Coya Therapeutics, Inc. (NASDAQ:COYA) Target Price at $16.00

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $16.00.

A number of research analysts recently commented on the company. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. BTIG Research upped their target price on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Friday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a report on Monday, November 24th.

Coya Therapeutics Price Performance

COYA opened at $5.49 on Friday. The firm has a market cap of $114.85 million, a P/E ratio of -4.95 and a beta of 0.20. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The company has a 50 day simple moving average of $6.15 and a two-hundred day simple moving average of $6.06.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $3.70 million. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%. Equities analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently bought and sold shares of the business. Prosperity Wealth Management Inc. increased its holdings in shares of Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Coya Therapeutics during the third quarter worth approximately $28,000. Charles Schwab Investment Management Inc. purchased a new stake in Coya Therapeutics during the first quarter valued at approximately $65,000. Lantern Wealth Advisors LLC bought a new stake in shares of Coya Therapeutics in the 3rd quarter valued at approximately $66,000. Finally, Jane Street Group LLC lifted its stake in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.